Audit: QRS - Rapamycin for Health & Longevity

Audit conducted on 28/08/2026 18:09 using AI4L + evidence-mcp / Opus 5

Iterations

Summary

Items Count
Total 93
Passed 83
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All protocol values (5–7 mg weekly, 2–3 mg start, morning empty stomach), time-to-effect values, benefit/risk items, gate items, marker targets and cadence trace to ER Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications and Monitoring Protocol & Defining Success.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 marker_11_target retains “No established target; tracked against baseline” (ER: “No established target on this drug; track the change from the individual’s own baseline instead”); marker_11_why retains “reported but unquantified”.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Absolute contraindications from the ER stay in the stop gate; ER “Caution”/”Monitor” bullets stay in the caution gate. No tier or severity shift found.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Gate content comes only from Key Interactions & Contraindications; benefits only from Expected Benefits; risks only from Potential Risks & Side Effects. No modifying-factor content leaked into any gate.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 The QRS carries no PMIDs, no NCT IDs, no expert names and no brand names. All named agents (ketoconazole, ritonavir, diltiazem, verapamil, rifampin, phenytoin, St. John’s wort, cimetidine, omeprazole, ibuprofen, naproxen, simvastatin, lovastatin, resveratrol, quercetin, berberine, black pepper extract, spermidine) appear in the ER for the same fact.
1.6 The QRS does not introduce new attributions. 🟢 No attributions of any kind in the QRS.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Matches the ER’s measured, sceptical register (“An experiment, not an established intervention”).
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Technical precision in gates and monitoring, plain language in At-A-Glance, no hedging or alarmism.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Descriptive framing throughout (“Protocols hold eight weeks”, “Commercial tablets preferred over compounded”).
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No imperatives directed at a reader; doses and thresholds are reported as protocol practice, and the footer disclaimer is intact.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 No occurrences of “recommend”, “advise”, “should” directed at a reader.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person pronouns anywhere in the document.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms retained (CYP3A4, Child-Pugh Class C, apolipoprotein B) are load-bearing decision-gate and biomarker names carried verbatim from the ER; elsewhere plain equivalents are used (“raised blood fats”, “lowered blood counts”, “mouth ulcers”).
2.8 Information is presented in a concise and very compact manner 🟢 Gate items 3–12 words, benefit and risk tiers are bare semicolon-separated headings, marker “Why” cells 3–6 words.
2.9 It DOES NOT address the reader directly 🟢 Confirmed: no “you”/”your”/”yours” in the source.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Sheet assumes prescription access, trough-level testing and quarterly panels — squarely this audience.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Fasted weekly dosing, grapefruit exclusion, 11-marker panel and surgical pauses are all presented without softening.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 No general-population framing or simplification.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 At-A-Glance names the narrowness of human gains and the documented costs, matching the ER’s own weighting for an off-label longevity user.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 “anti-aging” does not appear; “longevity” is used (action_1_label “Standard longevity regimen”).
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 “tablets”, “commercial tablets”, “compounded”, “trough”, “stomatitis”-equivalent “mouth ulcers” and “painkillers” all mirror the ER’s own register (ER bullet label: “Over-the-counter acid reducers and painkillers”). No colloquialisms introduced.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fourteen fixed strings verified byte-identical to [qrs_template].
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All 34 template variable names present; the only additional names are the repeatable marker_#_* (11 rows) and qualitative_item_# (6 items) expansions the template defines.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 The three non-variable spans (website="evidence_review", website="audit", website="full_review") are identical to the template; CSS block, footer and disclaimer unchanged.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No ER section feeding the QRS is empty; every benefit and risk tier, both gate lists, the protocol, monitoring and qualitative sections are populated in the ER.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 action_1_label “Standard longevity regimen”, action_2_label “Conservative escalation approach”, action_3_label “Best time of day” are the ER’s bold labels verbatim; all 11 monitoring row labels match the ER biomarker table’s first column verbatim.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Time-to-effect labels (“Body composition”, “Laboratory changes”, “Blood levels”) are taken from the ER’s own wording inside the Time to effect bullet; no invented labels.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji in the source; the ER’s ⚠️ Conflicted markers were correctly dropped. Tiering is carried by <strong> labels and the .benefits / .risks CSS palettes.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Every section is condensed rather than transcribed: ER contraindication bullets with rationale reduced to bare facts, benefit and risk headings stripped of magnitudes and conflict markers, marker “Why” cells reduced to 3–6 words, cadence paragraph reduced to one sentence. No section carries elaboration beyond the mandatory completeness required by items 8.2, 9.2, 14.2 and 15.2.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Lines 2–14: the comment opens on line 2, immediately after <!doctype html> on line 1, and precedes the template comment on line 16.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening --- on line 3, closing --- on line 13; the preamble text “QRS — Metadata (invisible, parsed by audit tooling)” sits before the opening delimiter.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Entirely inside an HTML comment; no metadata value is repeated in the header, footer or body.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration: "00:03" is quoted, correctly, because it contains a colon. All other values unquoted and untrimmed of nothing.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 Line 4: er_filename: rapamycin_2026-0828-1219_Opus_ER.md, which resolves to the actual source ER.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of [qrs_prompt].
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 Line 6: qrs_creation_date: 2026-0828-1639, correct format.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 Line 7: qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 “Opus” is a single word with no version or qualifier.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 Line 8: qrs_creator_ai_fullname: Opus 5.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 5” = nickname + version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 Line 9: qrs_filename: rapamycin_2026-0828-1219_Opus_QRS.html, matching the file on disk.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Re-verified across all nine keys, including the added git_user: evipedia-3 and git_issue: 5566; only the colon-bearing duration is quoted.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 Line 22: Rapamycin for Health &amp; Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 Line 417: Rapamycin for Health &amp; Longevity.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 Line 421: 08/28/2026, correctly derived from qrs_creation_date: 2026-0828-1639.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Line 425: Opus 5, matching the frontmatter.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header contains only the title and the template subline; the ER’s “Also known as: Sirolimus, Rapamune, AY-22989, RAPA” line was correctly not carried over.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Five sentences tracking the Conclusion’s structure: what it is, the animal result, the narrow human gains, the documented costs, the verdict.
7.2 [at_a_glance] is no longer than 60 words 🟢 58 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 “blocks the cell’s central growth switch”, “lengthens life more consistently than anything else tested”, cancer/vaccine/lean-tissue-in-women gains, the cost list and “an experiment rather than an established intervention” all map to distinct sentences of the ER Conclusion.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No acronyms; “mTOR” rendered as “the cell’s central growth switch”, “hyperlipidemia” as “raised blood fats”, “cytopenias” as “lowered blood counts”.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial names, years, sample sizes or p-values.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No hazard ratios, relative risks, percentages or confidence intervals.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All ten stop items trace to that ER section, including its “Populations who should avoid Rapamycin” list.
8.2 [stop_items] represent the Contraindications from the ER 🟢 All three ER absolute/temporary contraindication bullets (strong CYP3A4 inhibitors, cyclosporine, elective surgery / dental implants / cosmetic procedures) and all nine “Populations who should avoid” entries are represented, with the surgery bullet and the “within four weeks of planned surgery” population correctly merged into one item.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Ten discrete <li> elements inside the stop_items span (lines 557–570).
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 No dashes of any kind in the stop list; ER rationale such as “They can raise blood levels several-fold and produce immunosuppressive exposure from a longevity dose” and “for whom clearance is markedly reduced” was correctly stripped.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “(four weeks before until healed)”, “(Child-Pugh Class C)”, “stage 4+ (under 30 mL/min/1.73 m²)”, “over 300 mg/day”, “above 500 mg/dL until corrected”, “under 1,500/µL”, “under 100,000/µL”, “(either sex)”, “(outside transplant care)” all preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses; verified no </> symbols appear in any parenthetical there.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 The ER identifies numerous such populations and the section is correspondingly populated, so the constraint holds.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All nine caution items trace to that ER section’s bulleted interaction list.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 All nine non-contraindicated ER interaction bullets are present (moderate CYP3A4 inhibitors, grapefruit/Seville orange, CYP3A4 inducers, OTC acid reducers and painkillers, live attenuated vaccines, statins, ACE inhibitors, enzyme-shifting supplements, additive-pathway supplements). The three absolute/temporary contraindications (strong inhibitors, cyclosporine, procedures) are correctly excluded here and placed in the stop gate.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Nine discrete <li> elements inside the caution_items span (lines 578–594).
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 No dashes in the caution list; ER rationale such as “Levels typically rise by roughly one-and-a-half to two-fold” and the ACE-inhibitor angioedema explanation was correctly stripped.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Example drug lists preserved and trimmed rather than dropped: “(diltiazem, verapamil)”, “(rifampin, phenytoin, St. John’s wort)”, “(cimetidine, omeprazole, ibuprofen, naproxen)”, “(yellow fever, live zoster)”, “(resveratrol, quercetin, berberine, black pepper extract)”, “(spermidine, extended fasting, leucine restriction)”. The ACE-inhibitor parenthetical is a definitional gloss, not a qualifier, and is correctly dropped under 9.4.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses.
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 The ER identifies twelve such bullets and the section is correspondingly populated, so the constraint holds.
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 All three action cells derive from the ER Therapeutic Protocol section (plus its Formulation bullet for the action_1 sub-line).
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Dose (“Standard longevity regimen”), titration (“Conservative escalation approach”) and timing (“Best time of day”) are the three decision-bearing bullets; the remaining ER bullets are modifiers, pharmacology or attributed variant protocols.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER Therapeutic Protocol section contains thirteen bullets, so all three sets are used.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All nine fields populated: e.g. action_2 = “Conservative escalation approach” / “2–3 mg weekly to start” / “Protocols hold eight weeks, then step up 1–2 mg if trough and counts allow.”

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 The ER’s Time to effect bullet names exactly three horizons — blood levels (2–3 weeks), laboratory changes (1–3 months), body composition (a full year) — and all three are carried.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Body composition leads: it is the only horizon tied to a benefit tier in the ER (“Lean Mass and Physical Function”). Laboratory changes and blood levels, which map to no benefit, follow.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three distinct time-to-effect aspects exist in the ER, so all three sets are used.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 All nine fields populated; the sub-lines add ER-sourced context (“There is no felt effect to wait for.”, “Chiefly lipid shifts, the most reproducible metabolic effect.”, “First trough level at four weeks, and after any dose change.”).
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides an explicit Time to effect bullet under Practical Considerations, so the section is correctly retained.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 All twelve benefit entries are the ER’s own Expected Benefits sub-headings.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present and populated (lines 527–547).
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each entry is the bare ER heading; the “Magnitude:” paragraphs (hazard ratios, percentages, PMID links) and the ⚠️ Conflicted qualifiers were all stripped.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in any benefits span.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A The ER populates all four benefit tiers (1 high, 1 medium, 5 low, 5 speculative), so no span needs hiding.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 All fifteen risk entries are the ER’s own Potential Risks & Side Effects sub-headings.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present and populated (lines 606–628).
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each entry is the bare ER heading; frequencies (67% stomatitis, relative risk 6.97, 4–11% pneumonitis) and ⚠️ Conflicted qualifiers were all stripped.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in any risks span; the ER’s glosses such as “(painful ulcers of the mouth lining)” and “(low platelets)” are absent.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A The ER populates all four risk tiers (7 high, 2 medium, 4 low, 2 speculative), so no span needs hiding.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Rows and cadence derive from the ER Monitoring Protocol & Defining Success section and its biomarker table.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All 11 rows of the ER biomarker table are present in order, with targets and rationales condensed but unchanged in substance (sirolimus trough, CBC, lipid panel with ApoB, fasting insulin, fasting glucose, HbA1c, hs-CRP, eGFR, urine ACR, ALT, reproductive markers).
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Line 771 carries the full ER cadence: four-week drug level and blood count including after dose change or new interacting medication, full panel at three months, then every six months.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 All six items derive from the ER’s “Qualitative markers are tracked alongside the laboratory panel” list.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All six ER qualitative bullets present: mouth and gum comfort, minor-infection frequency and duration, healing speed, training recovery and strength progression, energy and cognitive clarity, joint comfort and pain.

Issues 28/08/2026 18:09

Pass rate 100.00%. No issues found.

Issues 28/08/2026 18:00

  1. 4.5 — Sheet overflows one A4 page: The combined content of the Contraindications gate (10 items wrapping to roughly 19 lines) and the Monitoring table (11 rows wrapping to roughly 18 lines) fills close to an entire A4 page on its own, and the estimated total rendered height is roughly 1.9 pages once the header, At-A-Glance, Protocol panel, Benefits, Risks and Qualitative Assessment cards are added.

Fixes 28/08/2026 18:00

  1. 4.5 — Contraindications gate condensed: Trimmed all ten stop items to their key fact while keeping every threshold and qualifier, e.g. “Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) or inducers that cannot be substituted” became “Non-substitutable strong CYP3A4 inhibitors or inducers (ketoconazole, ritonavir)”.
  2. 4.5 — Key Interactions gate condensed: Shortened the two longest supplement items and the vaccine item, e.g. “Supplements with additive effects on the same pathway (berberine, high-dose spermidine, extended fasting, leucine restriction)” became “Additive pathway effects (spermidine, extended fasting, leucine restriction)”.
  3. 4.5 — Monitoring table condensed: Cut the “Why” cells to their core statement across nine of the eleven rows (e.g. “Marrow suppression, the most consistent laboratory effect” to “Marrow suppression”), which also frees column width so the Marker and Target cells wrap onto fewer lines. All eleven markers and every numeric target were retained.
  4. 4.5 — Cadence, protocol and qualitative text tightened: Merged the cadence sentence’s four-week restart rule into the first clause, and trimmed the six Qualitative Assessment items and the At-A-Glance summary (58 words, from 59); this also repaired the dangling “against own history” phrasing in qualitative item 3.

Issues 28/08/2026 17:53

  1. 9.4 — Live-vaccine item carries trailing clause: The Key Interactions item at lines 599–600 appends the severity grade “; caution to contraindication by dose” after the drug list, while the eight sibling items all strip the ER’s grade (“Caution.”, “Monitor.”) and the gate heading already conveys it.

Fixes 28/08/2026 17:53

  1. 9.4 — Live-vaccine trailing clause stripped: Shortened the Key Interactions item from “Live attenuated vaccines (yellow fever, live zoster, oral typhoid); caution to contraindication by dose” to “Live attenuated vaccines (yellow fever, live zoster, oral typhoid)”, matching how the eight sibling items drop the ER’s severity grade.

Issues 28/08/2026 17:46

  1. 1.3 — Compounded formulation ruled out: action_1_sub (line 457) states “Commercial tablets, not compounded”, strengthening the ER’s “Commercial sirolimus tablets are preferred over compounded capsules” (ER line 437) into an absolute prohibition, while ER line 463 explicitly provides for compounded product where it is unavoidable.
  2. 8.4 — Duplicate surgical contraindication: The surgical gate is split across two overlapping stop_items, line 572 “Surgery, dental implants, cosmetic procedures (temporary, around the procedure)” and line 580 “Within four weeks of planned surgery; unhealed wound”, where a single merged item would carry both ER facts more concisely.

Fixes 28/08/2026 17:46

  1. 1.3 — Compounded formulation no longer ruled out: Changed action_1_sub from “Commercial tablets, not compounded” to “Commercial tablets preferred over compounded”, matching the ER’s stated preference rather than an absolute prohibition.
  2. 8.4 — Surgical contraindications merged: Combined the two overlapping stop_items into one, “Surgery, dental implants, cosmetic procedures (temporary, from four weeks before until the wound is healed)”, preserving the four-week window and the unhealed-wound condition while removing the duplicate item.

Issues 28/08/2026 17:31

  1. 7.2 — At-A-Glance exceeds word budget: The [at_a_glance] span (lines 433-439) runs to 61 words against the 60-word limit set by item 7.2.
  2. 9.5 — Supplement name abbreviated: The eighth [caution_items] entry (lines 601-604) shortens the ER’s “black pepper extract” to “black pepper”, turning a named supplement into an ordinary food and changing what the interaction refers to.

Fixes 28/08/2026 17:31

  1. 7.2 — At-A-Glance trimmed to word budget: Reduced [at_a_glance] from 61 to 59 words by changing “It extends life in animals” to “It extends animal lifespan” and replacing the standalone em-dash after “human gains are narrow” with a colon.
  2. 9.5 — Supplement name restored: Restored the ER’s full name “black pepper extract” in the eighth [caution_items] entry, replacing the abbreviated “black pepper”.

Issues 28/08/2026 17:27

  1. 2.15 — Colloquial clipping “lab”: marker_2_why (line 683) reads “the most consistent lab effect”; the ER writes “laboratory effect” and the QRS itself uses “Laboratory changes” at time_2_label, so the informal clipping is both non-formal and internally inconsistent.

Fixes 28/08/2026 17:27

  1. 2.15 — Colloquial clipping “lab”: Changed marker_2_why from “the most consistent lab effect” to “the most consistent laboratory effect”, matching the ER’s wording and the QRS’s own “Laboratory changes” label.

Issues 28/08/2026 17:19

  1. 1.3 — Qualifiers dropped, claims broadened: time_2_sub (line 513) states “the most reproducible effect” where the ER says “the most reproducible metabolic effect”, and marker_5_why (line 720) states “Metabolic drift the drug can cause” where the ER limits it to “the metabolic drift the drug can cause at higher exposure”.
  2. 4.2 / 4.3 — Interaction labels paraphrased: Three caution_items labels deviate from the ER’s bold labels: “Supplements affecting the same enzyme” (line 599) for “Supplements that inhibit or induce the same enzyme”, “Supplements adding to the same pathway” (line 603) for “Supplements with additive effects on the same pathway”, and “Acid reducers and painkillers” (line 591) for “Over-the-counter acid reducers and painkillers”.

Fixes 28/08/2026 17:19

  1. 1.3 — Metabolic qualifier restored: Changed time_2_sub from “the most reproducible effect” to “the most reproducible metabolic effect”, matching the ER, and restored “at higher exposure” to marker_5_why so the metabolic-drift claim keeps its ER limiting qualifier.
  2. 4.2 / 4.3 — Interaction labels restored verbatim: Replaced the three paraphrased caution_items labels with the ER’s bold labels: “Over-the-counter acid reducers and painkillers”, “Supplements that inhibit or induce the same enzyme”, and “Supplements with additive effects on the same pathway”.

Issues 28/08/2026 17:09

  1. 4.5 — Sheet overflows A4 by 2x: The laid-out content measures roughly 2222 px against a 1032 px A4 print budget (≈2.15 pages), driven mainly by the 11-row Monitoring card (≈629 px), the two decision gates (≈439 px) and the Protocol panel (≈274 px); no section has been condensed to a per-section budget.
  2. 1.1 — CYP3A4 drug list misattributed: stop_items item 1 (lines 571-572) attaches the six-drug list “(ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, cobicistat)” to “inhibitors or inducers”, but the ER presents that list exclusively as strong CYP3A4 inhibitors (ER line 355) and names none of them as an inducer.

Fixes 28/08/2026 17:09

  1. 1.1 — CYP3A4 drug list misattributed: Restructured stop_items item 1 from “Strong CYP3A4 inhibitors or inducers that cannot be substituted (ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, cobicistat)” to “Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) or inducers that cannot be substituted”, so the named drugs attach only to inhibitors as the ER has them.
  2. 4.5 — Contraindications gate condensed: Trimmed all eleven stop_items to their key fact while keeping every threshold, stage and time window (e.g. “Active bacterial, viral or fungal infection, or untreated latent tuberculosis” to “Active infection, or untreated latent tuberculosis”; “Within four weeks of planned surgery, or unhealed surgical or traumatic wound” to “Within four weeks of planned surgery; unhealed wound”). Gate height fell from ~427 px to ~337 px.
  3. 4.5 — Key Interactions gate condensed: Shortened all nine caution_items and trimmed the longest example-drug lists as 9.5 permits, retaining the “high-dose” qualifiers on resveratrol and spermidine and the severity qualifier on live vaccines. Gate height fell from ~387 px to ~297 px.
  4. 4.5 — Monitoring table condensed: Rewrote eight “Why” cells and three “Target” cells to single-line form (e.g. “Confirms actual exposure, which dose alone does not predict” to “Dose alone does not predict actual exposure”; “Under 25 U/L in men, under 20 U/L in women” to “Under 25 U/L men, 20 U/L women”) and shortened monitoring_cadence, with all eleven markers and every numeric target retained. Card height fell from ~629 px to ~510 px.
  5. 4.5 — Protocol panel condensed: Reduced all three action_#_sub cells and two time_#_sub cells from three rendered lines to two (e.g. “At least one hour before or two hours after food; the whole weekly dose is taken at once.” to “One hour before or two hours after food; whole weekly dose at once.”). Panel height fell from ~274 px to ~244 px.
  6. 4.5 — Residual overflow: Total laid-out height fell from ~2222 px to ~1983 px against the 1032 px A4 budget. The remainder cannot be removed by condensation alone: items 8.2, 9.2, 12.1, 13.1, 14.2 and 15.2 each mandate carrying the ER’s full inventory (11 contraindications, 9 interactions, 28 tiered benefit and risk entries, 11 biomarkers, 6 qualitative markers), which exceeds one A4 page for this ER.

Issues 28/08/2026 16:59

  1. 4.5 — Sheet overflows one A4 page: Estimated rendered height is roughly 480 mm against the ~273 mm available inside the print .sheet padding; the 11-item Contraindications gate and the 11-row Monitoring table alone consume about 200 mm, and per-item wording across the Protocol, Monitoring, Cadence and Qualitative Assessment blocks was not condensed toward the one-page budget.
  2. 2.5 — Imperative in protocol value cell: [action_2_value] reads “Start 2–3 mg weekly”, a bare imperative that instructs rather than presents, unlike the nominal sibling cells “5–7 mg weekly” and “Morning, empty stomach”.

Fixes 28/08/2026 16:59

  1. 2.5 — Imperative removed from protocol value: [action_2_value] changed from “Start 2–3 mg weekly” to “2–3 mg weekly to start”, making it nominal like its sibling cells rather than an instruction to the reader.
  2. 4.5 — Protocol subs condensed: [action_1_sub] shortened from “Commercial sirolimus tablets, preferred over compounded capsules, taken on the same day each week and away from food.” to “Commercial tablets preferred over compounded capsules; same day each week, away from food.”; [action_2_sub] “1 to 2 mg” tightened to “1–2 mg”.
  3. 4.5 — Monitoring cells tightened: Six marker cells trimmed of leading verbs and redundant tails (e.g. [marker_2_why] “Detects the drug’s most consistent laboratory effect, marrow suppression” → “Marrow suppression, the drug’s most consistent laboratory effect”; [marker_6_why] dropped “smoothing daily variation”), with every ER-sourced target value left unchanged.
  4. 4.5 — Cadence line condensed: [monitoring_cadence] reduced from four rendered lines to three by dropping “Whole-blood” and “a”/”any” filler, retaining the four-week, three-month and six-month intervals and the restart trigger.
  5. 4.5 — Qualitative items condensed: Four of the six items shortened (e.g. “Recovery quality after hard training sessions, and whether strength is still progressing” → “Recovery after hard training, and whether strength is still progressing”), keeping all six ER markers.
  6. 4.5 — Contraindication wording trimmed: Two [stop_items] shortened (“including untreated latent tuberculosis” → “or untreated latent tuberculosis”; “or an unhealed surgical or traumatic wound” → “or unhealed surgical or traumatic wound”). All 11 items and every threshold, staging and time-window qualifier were retained, since items 8.2 and 8.5 forbid dropping them; the sheet therefore remains longer than one A4 page.

Issues 28/08/2026 16:51

  1. 2.8 / 11.4 — Time to Effect subs are redundant: time_3_sub (line 529) “Blood levels stabilize within two to three weeks” restates label “Blood levels” and value “2–3 weeks” verbatim; time_2_sub (line 518) “Laboratory changes such as lipid shifts appear here” ends in a dangling deictic and drops the ER’s actual “within one to three months”; time_1_sub (lines 505-506) opens by repeating “Body composition” / “A full year”. action_1_sub (lines 457-458) also repeats “Commercial” across two sentences.

Fixes 28/08/2026 16:51

  1. 2.8 / 11.4 — Redundant time-to-effect subs rewritten: time_1_sub reduced to the ER’s “There is no felt effect to wait for.” (dropping the restatement of label and value); time_2_sub changed from “Laboratory changes such as lipid shifts appear here.” to “Chiefly lipid shifts, the most reproducible metabolic effect.”; time_3_sub changed from “Blood levels stabilize within two to three weeks.” to “The first trough level is drawn at roughly four weeks, and after any dose change.”
  2. 2.8 — Duplicated wording in protocol sub: action_1_sub condensed from two sentences repeating “Commercial” to one: “Commercial sirolimus tablets, preferred over compounded capsules, taken on the same day each week and away from food.”

Issues 28/08/2026 16:45

  1. 2.5 / 2.6 / 2.9 — Imperative mood addresses reader: [action_2_sub] at line 471 reads “Hold eight weeks, then step up 1 to 2 mg…” and [marker_11_target] at line 806 reads “track the change from own baseline”; both are imperatives, where the ER frames the same content descriptively (“Protocols start at 2 to 3 mg weekly, hold eight weeks…”, ER line 415).
  2. 12.3 / 12.4 — “(conflicted)” qualifier in Benefits: [benefits_low] lines 548–549 preserve the parenthetical qualifier “(conflicted)” on “Lean mass and physical function” and “respiratory tract infections”, which the tier label already encodes.
  3. 13.3 / 13.4 — “(conflicted)” qualifier in Risks: [risks_low] lines 636–638 preserve the parenthetical qualifier “(conflicted)” on “Impaired glucose tolerance”, “increased susceptibility to infection” and “acne-like eruptions and other skin complaints”, which the tier label already encodes.

Fixes 28/08/2026 16:45

  1. 2.5 / 2.6 / 2.9 — Imperative mood removed: [action_2_sub] changed from “Hold eight weeks, then step up 1 to 2 mg…” to “Protocols hold eight weeks, then step up 1 to 2 mg…”, and [marker_11_target] changed from “track the change from own baseline” to “tracked against own baseline”, so neither addresses the reader.
  2. 12.3 / 12.4 — “(conflicted)” stripped from Benefits: Removed the parenthetical “(conflicted)” from “Lean mass and physical function” and “respiratory tract infections” in [benefits_low], leaving the tier label to carry the evidence strength.
  3. 13.3 / 13.4 — “(conflicted)” stripped from Risks: Removed the parenthetical “(conflicted)” from “Impaired glucose tolerance”, “increased susceptibility to infection” and “acne-like eruptions and other skin complaints” in [risks_low].